Lipoprotein Lipase
Lipoprotein Lipase (LPL, also known as LIPD) is a key enzyme in triglyceride metabolism. It hydrolyses triglycerides carried in circulating chylomicrons and very low density lipoproteins (VLDL), supporting lipid clearance from the blood stream. Browse Assay Genie's current range of Lipoprotein Lipase research reagents below, or read on for the biology behind the target.
Lipoprotein lipase catalyses the hydrolysis of triglycerides from circulating chylomicrons and VLDL, and so plays an important role in lipid clearance from the blood stream, lipid utilisation and lipid storage. It has both phospholipase and triglyceride lipase activities, but it is primarily a triglyceride lipase, with low but detectable phospholipase activity. It also mediates margination of triglyceride-rich lipoprotein particles in capillaries. NCBI describes two functions for LPL: triglyceride hydrolase, and ligand or bridging factor for receptor-mediated lipoprotein uptake.
The enzyme is recruited to its site of action on the luminal surface of the vascular endothelium by binding to GPIHBP1 and to cell surface heparan sulfate proteoglycans. It is found at the cell membrane and is secreted into the extracellular space and extracellular matrix. The LPL gene is expressed in heart, muscle and adipose tissue, and the active protein functions as a homodimer. Researchers working with the LPL protein often study it alongside its endothelial anchoring partners.
LPL belongs to the lipase family within the AB hydrolase superfamily, and HGNC places it in the lipases gene group. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in the LPL gene are linked to many disorders of lipoprotein metabolism. The mouse and rat orthologs are both named Lpl, which makes rodent models a common route for studying lipid handling.
LPL is a key enzyme in triglyceride metabolism, hydrolysing triglycerides from chylomicrons and VLDL.
Its activity underpins lipid clearance from the blood stream, as well as lipid utilisation and storage.
LPL acts on the luminal endothelial surface after binding GPIHBP1 and heparan sulfate proteoglycans, mediating lipoprotein margination in capillaries.
LPL deficiency causes type I hyperlipoproteinemia, and milder variants are linked to many disorders of lipoprotein metabolism.
Lipoprotein lipase hydrolyses triglycerides from circulating chylomicrons and VLDL, contributing to lipid clearance, utilisation and storage. It is primarily a triglyceride lipase with low phospholipase activity. It also acts as a bridging factor for receptor-mediated lipoprotein uptake and mediates margination of lipoprotein particles in capillaries.
The HGNC-approved symbol is LPL, for lipoprotein lipase, and LIPD is a recorded alias. The enzyme is classified as EC 3.1.1.34 and sits in the lipase gene group. UniProt lists the protein under the name Lipoprotein lipase.
Severe LPL mutations cause LPL deficiency, which results in type I hyperlipoproteinemia. Less extreme variants are linked to many disorders of lipoprotein metabolism. Mouse and rat both have an ortholog named Lpl; check the datasheet of any product for its validated reactivity.
Binding partners and lipid-metabolism targets related to lipoprotein lipase with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P06858; product specifications from Assay Genie datasheets.